Evidence map›Paper›PMID 23349887›Full record

ArticlePloS one2013

Differential effects of rapamycin and dexamethasone in mouse models of established allergic asthma.

Elizabeth M Mushaben, Eric B Brandt, Gurjit K Khurana Hershey, Timothy D Le Cras

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Rational targeting Cdc42 restrains Th2 cell differentiation and prevents allergic airway inflammation.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2019
    Article
  10. Article
  11. Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches.American journal of respiratory cell and molecular biology · 2017
    Review
  12. Review
  13. Article
  14. Review
  15. The potential mechanistic link between allergy and obesity development and infant formula feeding.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2014
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Elizabeth M MushabenDivision of Pulmonary Biology, Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati School of Medicine, Cincinnati, Ohio, USA.
Eric B Brandt
Gurjit K Khurana Hershey
Timothy D Le Cras
Cincinnati Children's Hospital Medical Center · USUniversity of Cincinnati · US

Funding

Molecular Epidemiology in Children's Environmental Health Training Program (MECEH)T32ES010957 · NIEHS · UNIVERSITY OF CINCINNATI · PI Kelly J Brunst · 2001 to 2026
$11.1M
Impact of Early Life Diesel Exposure on Immune Patterning and Lung Structure/FuncR01HL097135 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI KHURANA HERSHEY, GURJIT K., LE CRAS, TIMOTHY DAVID · 2009 to 2013
$2.5M
NHLBI NIH HHS HL097135NHLBI NIH HHS R01 HL097135NIEHS NIH HHS T32 ES010957PHS HHS U19A170235
6 · The paper itself

Abstract

The mammalian target of rapamycin (mTOR) plays an important role in cell growth/differentiation, integrating environmental cues, and regulating immune responses. Our lab previously demonstrated that inhibition of mTOR with rapamycin prevented house dust mite (HDM)-induced allergic asthma in mice. Here, we utilized two treatment protocols to investigate whether rapamycin, compared to the steroid, dexamethasone, could inhibit allergic responses during the later stages of the disease process, namely allergen re-exposure and/or during progression of chronic allergic disease. In protocol 1, BALB/c mice were sensitized to HDM (three i.p. injections) and administered two intranasal HDM exposures. After 6 weeks of rest/recovery, mice were re-exposed to HDM while being treated with rapamycin or dexamethasone. In protocol 2, mice were exposed to HDM for 3 or 6 weeks and treated with rapamycin or dexamethasone during weeks 4-6. Characteristic features of allergic asthma, including IgE, goblet cells, airway hyperreactivity (AHR), inflammatory cells, cytokines/chemokines, and T cell responses were assessed. In protocol 1, both rapamycin and dexamethasone suppressed goblet cells and total CD4(+) T cells including activated, effector, and regulatory T cells in the lung tissue, with no effect on AHR or total inflammatory cell numbers in the bronchoalveolar lavage fluid. Rapamycin also suppressed IgE, although IL-4 and eotaxin 1 levels were augmented. In protocol 2, both drugs suppressed total CD4(+) T cells, including activated, effector, and regulatory T cells and IgE levels. IL-4, eotaxin, and inflammatory cell numbers were increased after rapamycin and no effect on AHR was observed. Dexamethasone suppressed inflammatory cell numbers, especially eosinophils, but had limited effects on AHR. We conclude that while mTOR signaling is critical during the early phases of allergic asthma, its role is much more limited once disease is established.

Indexed as

TOR Serine-Threonine KinasesAnimalsAsthmaBronchoalveolar Lavage FluidCD4-Positive T-LymphocytesDexamethasoneDisease Models, AnimalGoblet CellsHypersensitivityImmunoglobulin GInflammationInterleukin-4MicePyroglyphidaeSirolimusDexamethasoneImmunoglobulin GInterleukin-4mTOR protein, mouseSirolimusTOR Serine-Threonine Kinases

Identifiers

PMID23349887
PMCPMC3547928
OpenAlexW2039001867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.